stockrow
Saturday 7 November 2026
Export NIVF’s income statement to Excel — free account
NewGenIvf Group Limited
NIVF Healthcare Medical Care Facilities
NewGenIvf Group Limited’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 13.0% from fiscal 2024.
0.45
0.04
−8.16%
Follow NIVF
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 6 | 5 | 5 | 5 | — | (7.4%) | 65 | 180 | 271 | +285.4% | |
| Gross margin, % | — | — | — | — | — | — | 25.87 | 32.74 | 33.62 | 20.22 | — | (5.6) pt | ||||||
| EBT | — | — | — | — | — | — | 0 | 0 | (1) | 10 | — | +204.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | 5.79 | 2.11 | (17.68) | 205.84 | — | +200.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | 0 | 0 | 0 | 10 | 9 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 5,573,035.81 | 166.76 | 410,936.32 | 23,632.00 | — | (83.8%) | |||||
| Earnings | — | — | — | — | — | — | 4,422,501.00 | 3.53 | (1,140,822.00) | 60,910.53 | — | (76.0%) | ||||||
| Cash flow | — | — | — | — | — | — | 1,604,069.00 | (57.34) | (625,026.47) | (54,630.50) | 0.00 | n/m | ||||||
| Capex | — | — | — | — | — | — | (88,599.29) | (2.27) | (4,008.47) | (675.00) | 0.00 | (80.3%) | ||||||
| Free cash flow | — | — | — | — | — | — | 1,515,469.72 | (59.61) | (629,034.94) | (55,305.50) | 0.00 | n/m | ||||||
| Book value | — | — | — | — | — | — | 94,412.15 | 105.38 | (112,070.79) | 129,933.50 | 0.00 | +11.2% | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 0 | 0 | — | +472.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.17) | (0.16) | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 2 | (2) | (8) | (11) | (19) | n/m | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | +12.6% | ||||||
| Free cash flow | — | — | — | — | — | — | 2 | (2) | (8) | (11) | (20) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 0 | 1 | 0 | 5 | 1 | n/m | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | 2 | 3 | (1) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 0 | 3 | (1) | 26 | 26 | +536.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 31.58 | 3.52 | (13.01) | 54.43 | 0.00 | +54.4 pt | |||||
| ROIC | — | — | — | — | — | — | 313.44 | 0.83 | (186.26) | (22.86) | 0.00 | (336.3) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 7.78 | (59.49) | 80.63 | 0.00 | +80.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 70 | 76 | 87 | — | +11.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.07 | 0.07 | 0.05 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 2 Nov 2026
NewGenIvf Group Limited vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BTMD biote Corp. | $37.4M | 6.6× | — (loss-making) | −9.48% (below 0%: shrinking) | n/m | −174.16% (below 0%: shrinking) | 65.38% | (7.93%) | Compare |
| PIII P3 Health Partners Inc. | $28.1M | — (loss-making) | — | +8.60% (above 0%: growing) | n/m | −272.24% (below 0%: shrinking) | 22.26% | 10.67% | Compare |
| DCGO DocGo Inc. | $24.1M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −132.28% (below 0%: shrinking) | 30.52% | (24.41%) | Compare |
| CCM Concord Medical Services Holdings Limited | $10.0M | — (loss-making) | — (loss-making) | +37.65% (above 0%: growing) | n/m | −281.45% (below 0%: shrinking) | (13.15%) | 0.00% | Compare |
| AMS American Shared Hospital Services | $7.8M | — (loss-making) | 1.8× | +19.22% (above 0%: growing) | n/m | +195.82% (above 0%: growing) | 17.00% | (7.22%) | Compare |
| RHEP Adcare Health Systems Inc | $5.2M | 0.6× | — (loss-making) | +143.03% (above 0%: growing) | n/m | +224.45% (above 0%: growing) | 31.50% | (0.88%) | Compare |
| SYRA Syra Health Corp. | $1.1M | 14.7× | — | +51.50% (above 0%: growing) | n/m | +235.76% (above 0%: growing) | 46.34% | 11.73% | Compare |
| NVOS Novo Integrated Sciences, Inc. | $730.0K | — (loss-making) | — (loss-making) | −6.74% (below 0%: shrinking) | n/m | −111.85% (below 0%: shrinking) | 51.21% | (87.60%) | Compare |
| NIVF NewGenIvf Group Limited | $610.0K | — | — | — | — | — | — | — | |
| Median of peers | $8.9M | 6.6× | — | +13.91% | — | −122.06% | 31.01% | (4.05%) |